Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

212
Delayed Quote. Delayed BATS EUROPE - 01/30 04:55:00 pm
297.4000 DKK   +0.64%
01/30DJNovo Nordisk to Benefit From Dollar Strength in 2015
01/30DJNOVO NORDISK A/ : 4Q Net Profit Beats Estimates
01/27 NOVO NORDISK A/ : Clinical Trials: More than safety and efficacy
 SummaryChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Copenhagen Stock Exchange
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
297.2 297.4 298.4 299.9 295.5 Last
3929457 3694420 3038442 3151618 6602740 Volume
+1.43% +0.07% +0.34% +0.50% -1.47% Change
Company
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes Care and Biopharmaceuticals segments.The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of... 
Sector
Pharmaceuticals
Calendar
01/30Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO.B | DK0060534915 | 4-Traders
Full-screen chart
Financials ( DKK)
Sales 2015 100 900 M
EBIT 2015 40 458 M
Net income 2015 30 251 M
Finance 2015 13 146 M
Yield 2015 1,90%
Sales 2016 109 940 M
EBIT 2016 45 040 M
Net income 2016 35 341 M
Finance 2016 14 346 M
Yield 2016 2,20%
PER 2015 25,23
PER 2016 21,14
EV / Sales 2015 6,06x
EV / Sales 2016 5,55x
Capitalization 624 263 M
More Financials
Latest news on NOVO NORDISK A/S
01/30DJNovo Nordisk to Benefit From Dollar Strength in 2015
01/30DJNOVO NORDISK A/S : 4Q Net Profit Beats Estimates
01/30 NOVO NORDISK A/S : Secures FDA OK for Norditropin FlexPro 30 mg/3.0 mL for Patie..
01/29 NOVO NORDISK A/S : New Hydrogen Study Results Reported from Novo Nordisk (Sites ..
01/29 NOVO NORDISK A/S : Gets FDA OK for Norditropin FlexPro 30 mg/3.0 mL for Patients..
01/28 NOVO NORDISK A/S : Studies from Novo Nordisk Provide New Data on Biological and ..
01/28 NOVO NORDISK A/S : New Clinical Trials and Studies Study Findings Recently Were ..
01/28 NOVO NORDISK A/S : TransCelerate BioPharma Welcomes Merck %7E Co. and Novo Nordi..
More news
Sector news Pharmaceuticals - NEC
09:15a JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF